Ascendis Pharma A/S (ASND) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Q2 2025 Ascendis Pharma Earnings Conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 1-1 again. You may ask one question and one follow-up. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Scott Smith, Ascendis Pharma CFO. Please go ahead. Manu Tak, operator. And thank you, everyone, for joining our second quarter 2025 financial results conference call. I'm Scott Smith, executive vice president and chief financial officer at Ascendis Pharma. Joining me on today's call are Yen Muller-Mickelson, president and chief executive officer, Sherry Glass, chief business officer, Jay Wu, executive vice president and president, US market, Amy Hsu, executive vice president of Endocrine and Rare Disease Medical Sciences, and chief medical officer. Before we begin, I would like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may include, but are not limited to, statements regarding our commercialization and continued development of SkyTrofa and the Orbit Path, as well as certain financial expectations, our pipeline candidates, and our expectations with respect to their continued progress and potential commercialization. Our strategic plans, partnerships, and investments,...